Navigation Links
NeoStem's Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
Date:5/27/2010

NEW YORK, May 27 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced that the Company has been invited to present its adult stem cell technologies at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York City on June 1, 2010. SCIENCE is designed to bring together investors with industry executives, visionary researchers and clinicians and other stakeholders to highlight opportunities and discuss advances in the stem cell field.

Alan Harris, M.D., Ph.D., NeoStem's VP of Regenerative Medicine, Drug Development and Regulatory Affairs, has been selected to participate in the 11:30 am ET panel discussion on "Adult versus Embryonic" stem cells. Dr. Harris will highlight the positive attributes of and advances in adult stem cell research, as well as discuss the regenerative properties of very small embryonic-like stem cells without the controversy of traditional embryonic stem cells. The panel will be moderated by Martin Grumet, Ph.D., Professor of Cell Biology and Neuroscience, Division of Life Sciences, at Rutgers University. Additional panel participants will include Michael West, Ph.D., CEO of BioTime, Inc., and Michael Schuster, VP of Operations at Angioblast System, Inc.

At a 2:00 pm ET plenary session, Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors, will be a key speaker discussing "Autologous Approaches" to stem cell therapy, including the Company's experience as a pioneer in the field of autologous (one's own) adult stem cell banking and its potential applications for future therapies. Other speakers at this session will include Ronnda Bartel, Ph.D., the CSO of Aastrom Biosciences, Inc., Eldad Melamed, M.D., CMO of Brainstorm Cell Therapeutics and Madhusudan Peshwa, Ph.D., Executive VP of Cellular Therapies at MaxCyte, Inc.

Additionally, at 2:45 pm ET, Reverend Tomasz Trafny of the Vatican's Pontifical Council for Culture will be a keynote speaker at the conference to discuss the Church's growing support of the scientific and medical application of autologous adult stem cell and discuss the bioethical considerations. NeoStem and the Pontifical Council for Culture recently announced a joint initiative that unites their charitable organizations to expand research and raise awareness of adult stem cell therapies, including working on multiple collaborative activities to advance scientific research on adult stem cells, exploring their clinical application in the field of regenerative medicine and the cultural relevance of such a fundamental shift in medical treatment options.

"We are excited about another opportunity to highlight NeoStem's industry leading effort in the adult stem cell field, particularly with the recently announced joint initiative with the Pontifical Council for Culture," said Dr. Smith.

Stem Cell Investor & Executive Networking Conference Event (SCIENCE)

SCIENCE is hosted by National Securities Corporation and MD Becker Partners. The SCIENCE program is strategically designed to unite investors with industry executives to exchange information and highlight opportunities in the expanding stem cell universe. The event will bring together the founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to offer compelling presentations, share information, and discuss the future of the exciting field.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful application of the Company's technology, including VSELTM technology, to develop adult stem cell therapies, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 and the Company's Quarterly Report on Form 10-q filed with the Securities and Exchange Commission on May 17, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174
     Email: rsmith@neostem.com
     Web:   http://www.neostem.com

    CCG Investor Relations, Inc.
     Lei Huang, Account Manager
     Phone: +1-646-833-3417
     Email: lei.huang@ccgir.com
     Web:   http://www.ccgirasia.com

     Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):